Review links medication-raised blood pressure to better recovery in some stroke patients
The analysis found an association in selected noncardioembolic strokes, but the evidence was limited and came only from Asian cohorts.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers combined results from three studies of people with selected noncardioembolic ischemic strokes and early neurological worsening. The studies compared medication-induced hypertension, usually using phenylephrine to raise systolic blood pressure by 15% to 25%, with usual medical management.
Functional independence at 90 days was reported in 68.8% of people receiving induced hypertension and 50.5% of those in comparison groups. Bleeding into damaged brain tissue, called hemorrhagic transformation, was uncommon and was not statistically different between groups, but the estimate was very imprecise.
What the review examined
The researchers conducted a systematic review and meta-analysis of studies available through November 6, 2025. They included studies of induced hypertension started within 72 hours of acute ischemic stroke and reporting 90-day functional independence, defined as a score of 0 to 2 on the modified Rankin Scale. The three included studies contained 366 patients: 180 received induced hypertension and 186 received medical management. The abstract reports an average age of 65.8 years, 60.9% men, and an average initial stroke-severity score of 5.4. The included populations were described as selected noncardioembolic stroke patients with early neurological deterioration.
What the review concluded
Functional independence at 90 days occurred in 68.8% of the induced-hypertension group compared with 50.5% of the control group. In the pooled analysis, this corresponded to a risk ratio of 1.37, with a 95% confidence interval of 1.09 to 1.73. This is an association in the studies that were combined, not proof that raising blood pressure caused better recovery.
Hemorrhagic transformation occurred in 3.3% of the induced-hypertension group and 0.5% of the control group. The difference was not statistically significant, but the confidence interval was extremely wide, from 0.05 to 88.07, so the available data provide limited information about this safety outcome.
Where this may apply
These findings may be relevant only to patients resembling those studied: selected adults with noncardioembolic acute ischemic stroke, early neurological deterioration, and treatment begun within 72 hours. They should not be assumed to apply to all people with ischemic stroke, people with bleeding strokes, cardioembolic strokes, or populations unlike the exclusively Asian cohorts included here. The study does not establish that induced hypertension is beneficial or safe for any individual patient.
What this could mean
The findings address a difficult situation in which some people worsen neurologically soon after an ischemic stroke. They suggest that induced hypertension may be associated with better 90-day function in narrowly selected patients, but they do not show that it is appropriate for everyone with stroke or that it improves outcomes for other stroke types. The results also do not provide a reliable answer about uncommon bleeding complications.
Limitations & evidence assessment
Only three studies and 366 patients were included, so the overall evidence base was small. Most of the studies were retrospective rather than randomized, meaning that differences between treatment groups could have influenced the results. The studies were conducted exclusively in Asian cohorts, and treatment methods and patient populations varied. The safety analysis included few bleeding events and had a very wide confidence interval. The abstract does not provide enough detail to determine how consistently other important outcomes or possible confounding factors were assessed.
Why this evidence level: This was a meta-analysis, but it combined only three studies involving 366 people, and most of the underlying studies were retrospective. The findings are therefore less certain than those from several large, well-designed randomized trials.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
The Neurohospitalist · 2026 · DOI: 10.1177/19418744261474344
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
